Fennec Pharmaceuticals Inc

Company Profile

Fennec Pharmaceuticals Inc had its IPO on 2001-06-05 under the ticker symbol FENC.

The company operates in the Healthcare sector and Biotechnology industry. Fennec Pharmaceuticals Inc has a staff strength of 36 employees.

Stock update

Shares of Fennec Pharmaceuticals Inc opened at $8.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.93 - $8.38, and closed at $8.04.

This is a -0.86% slip from the previous day's closing price.

A total volume of 70,048 shares were traded at the close of the day’s session.

In the last one week, shares of Fennec Pharmaceuticals Inc have slipped by -3.94%.

Fennec Pharmaceuticals Inc's Key Ratios

Fennec Pharmaceuticals Inc has a market cap of $220.07 million, indicating a price to book ratio of 92.3152 and a price to sales ratio of 829.8398.

In the last 12-months Fennec Pharmaceuticals Inc’s revenue was $3.21 million with a gross profit of $1.45 million and an EBITDA of $-13009000. The EBITDA ratio measures Fennec Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fennec Pharmaceuticals Inc’s operating margin was -756.94% while its return on assets stood at -74.18% with a return of equity of -1005.59%.

In Q1, Fennec Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Fennec Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fennec Pharmaceuticals Inc’s profitability.

Fennec Pharmaceuticals Inc stock is trading at a EV to sales ratio of 722.2629 and a EV to EBITDA ratio of -12.0398. Its price to sales ratio in the trailing 12-months stood at 829.8398.

Fennec Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$21.82 million

Total Liabilities

$4.02 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Fennec Pharmaceuticals Inc ended 2023 with $21.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.82 million while shareholder equity stood at $-7339000.00.

Fennec Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $4.02 million in other current liabilities, 142804000.00 in common stock, $-209252000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.39 million and cash and short-term investments were $18.39 million. The company’s total short-term debt was $0 while long-term debt stood at $24.66 million.

Fennec Pharmaceuticals Inc’s total current assets stands at $21.66 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.68 million compared to accounts payable of $2.95 million and inventory worth $918000.00.

In 2023, Fennec Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Fennec Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$8.04

52-Week High

$10.85

52-Week Low

$5.265

Analyst Target Price

$16.33

Fennec Pharmaceuticals Inc stock is currently trading at $8.04 per share. It touched a 52-week high of $10.85 and a 52-week low of $10.85. Analysts tracking the stock have a 12-month average target price of $16.33.

Its 50-day moving average was $8.3 and 200-day moving average was $8.8 The short ratio stood at 17.79 indicating a short percent outstanding of 0%.

Around 1728.1% of the company’s stock are held by insiders while 4785.6% are held by institutions.